Atara Biotherapeutics, Inc.
ATRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.10 | -0.00 | 0.05 |
| FCF Yield | -5.04% | -7.77% | -44.01% | -17.26% |
| EV / EBITDA | -74.24 | 26.38 | 2.58 | -15.20 |
| Quality | ||||
| ROIC | -14.95% | 12.99% | 91.37% | 105.41% |
| Gross Margin | 96.67% | 96.85% | 79.18% | 79.25% |
| Cash Conversion Ratio | 2.27 | -3.07 | -0.74 | 1.93 |
| Growth | ||||
| Revenue 3-Year CAGR | 222.20% | 201.81% | 51.46% | 26.58% |
| Free Cash Flow Growth | -33.74% | 73.99% | -14.56% | -515.72% |
| Safety | ||||
| Net Debt / EBITDA | -15.87 | 0.21 | 1.01 | -1.77 |
| Interest Coverage | -3.90 | 3.29 | 38.15 | -12.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.64 |
| Cash Conversion Cycle | -199.01 | -286.25 | 2.04 | 87.36 |